文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

危重成人拔管后无创呼吸支持:系统评价与网络Meta分析

Noninvasive respiratory support following extubation in critically ill adults: a systematic review and network meta-analysis.
PubMed 文献 · Intensive Care Med · 2021-11-25
一句话结论与常规氧疗相比,NIPPV(OR 0.65)和HFNC(OR 0.63)均减少危重成人拔管后再插管,支持预防性应用而非恶化后补救。

该系统评价与网络Meta分析纳入36项RCT(6806例危重成人),评估拔管后NIPPV、HFNC、常规氧疗或联合策略对再插管的影响。与常规氧疗相比,NIPPV(OR 0.65,95%CI 0.52-0.82)和HFNC(OR 0.63,95%CI 0.45-0.87)均降低再插管(均为中等确定性);NIPPV与HFNC之间再插管无差异(OR 1.04,95%CI 0.78-1.38,低确定性)。两者均未降低短期死亡率。预防性应用时结果一致,补救性应用时未重现。

要点

  • 与常规氧疗相比,NIPPV降低再插管(OR 0.65,95%CI 0.52-0.82),中等确定性。
  • 与常规氧疗相比,HFNC降低再插管(OR 0.63,95%CI 0.45-0.87),中等确定性。
  • NIPPV与HFNC之间再插管发生率无差异(OR 1.04,95%CI 0.78-1.38),低确定性。
  • 与常规氧疗相比,NIPPV(OR 0.8,95%CI 0.61-1.04)和HFNC(OR 0.9,95%CI 0.66-1.24)均未降低短期死亡率。
  • 预防性应用无创呼吸支持时结果一致,补救性应用(出现恶化证据后)时未重现。

适用人群与场景

  • 危重成人拔管后,评估无创呼吸支持(NIPPV、HFNC、常规氧疗或联合)的随机对照试验人群。
  • 亚组包括再插管基线风险增高和降低的患者。

研究设计与关键结果

  • 研究类型:系统评价与网络Meta分析,纳入36项RCT,共6806例危重成人。
  • 主要结局:与常规氧疗相比,NIPPV降低再插管(OR 0.65,95%CI 0.52-0.82,中等确定性),HFNC降低再插管(OR 0.63,95%CI 0.45-0.87,中等确定性)。
  • NIPPV与HFNC比较:再插管发生率无差异(OR 1.04,95%CI 0.78-1.38,低确定性)。
  • 短期死亡率:与常规氧疗相比,NIPPV(OR 0.8,95%CI 0.61-1.04,中等确定性)和HFNC(OR 0.9,95%CI 0.66-1.24,低确定性)均未降低。
  • 敏感性分析:再插管基线风险增高的患者中效应量最大。
  • 多个亚组(包括高风险和低风险患者)结果一致;预防性应用时结果重现,补救性应用时未重现。

证据类型、等级与局限

  • 证据类型:系统评价与网络Meta分析,采用GRADE分级。
  • NIPPV和HFNC降低再插管均为中等确定性;NIPPV与HFNC比较为低确定性;HFNC对短期死亡率为低确定性,NIPPV为中等确定性。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,这些发现支持对危重成人预防性应用无创呼吸支持策略以减少拔管失败,但不支持在补救情况下(出现恶化证据后)应用。
  • 与常规氧疗相比,NIPPV和HFNC均可减少再插管;NIPPV与HFNC之间再插管无差异。
  • 再插管基线风险增高的患者中效应量最大。

指南或共识出处

  • Intensive Care Med 发表的系统评价与网络Meta分析(检索截至2021年10月)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Systematic review and network meta-analysis to investigate the efficacy of noninvasive respiratory strategies, including noninvasive positive pressure ventilation (NIPPV) and high-flow nasal cannula (HFNC), in reducing extubation failure among critically ill adults.

METHODS: We searched databases from inception through October 2021 for randomized controlled trials (RCTs) evaluating noninvasive respiratory support therapies (NIPPV, HFNC, conventional oxygen therapy, or a combination of these) following extubation in critically ill adults. Two reviewers performed screening, full text review, and extraction independently. The primary outcome of interest was reintubation. We used GRADE to rate the certainty of our findings.

RESULTS: We included 36 RCTs (6806 patients). Compared to conventional oxygen therapy, NIPPV (OR 0.65 [95% CI 0.52-0.82]) and HFNC (OR 0.63 [95% CI 0.45-0.87]) reduced reintubation (both moderate certainty). Sensitivity analyses showed that the magnitude of the effect was highest in patients with increased baseline risk of reintubation. As compared to HFNC, no difference in incidence of reintubation was seen with NIPPV (OR 1.04 [95% CI 0.78-1.38], low certainty). Compared to conventional oxygen therapy, neither NIPPV (OR 0.8 [95% CI 0.61-1.04], moderate certainty) or HFNC (OR 0.9 [95% CI 0.66-1.24], low certainty) reduced short-term mortality. Consistent findings were demonstrated across multiple subgroups, including high- and low-risk patients. These results were replicated when evaluating noninvasive strategies for prevention (prophylaxis), but not in rescue (application only after evidence of deterioration) situations.

CONCLUSIONS: Our findings suggest that both NIPPV and HFNC reduced reintubation in critically ill adults, compared to conventional oxygen therapy. NIPPV did not reduce incidence of reintubation when compared to HFNC. These findings support the preventative application of noninvasive respiratory support strategies to mitigate extubation failure in critically ill adults, but not in rescue conditions.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Fernando SM, Tran A, Sadeghirad B, et al. Noninvasive respiratory support following extubation in critically ill adults: a systematic review and network meta-analysis. Intensive Care Med. 2021. PMID: 34825256. doi:10.1007/s00134-021-06581-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。